Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Clinical Trials and Industry Influence: Major Report

June 2, 2000

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

A major health policy overview on what is happening in clinical trials -- and on pharmaceutical-industry manipulation of the design, conduct, and reporting of trials to get commercially favorable results(1) -- was published May 18 in the New England Journal of Medicine; it is available on the Web at http://www.nejm.org/content/2000/0342/0020/1539.asp.

A related editorial,(2) "Is Academic Medicine for Sale," appeared in the same issue, and is available at http://www.nejm.org/content/2000/0342/0020/1516.asp.

An example from the article:

"If a drug is tested in a healthier population (younger, with fewer coexisting conditions and with milder disease) than the population that will actually receive the drug, a trial may find that the drug relieves symptoms and creates fewer adverse effects than will actually be the case. Rochon et al. found that only 2.1 percent of subjects in trials of nonsteroidal anti-inflammatory drugs were 65 years of age or older, even though these drugs are more commonly used and have a higher incidence of side effects in the elderly... Rochon et al. concluded that trials of nonsteroidal anti-inflammatory drugs always found the sponsoring company's product superior or equal to the comparison product..."

Advertisement
Another section concerns the "guest-ghost syndrome," by which journal articles are increasingly ghostwritten by medical writers, based on information packets supplied to them by pharmaceutical companies -- and then signed by well-known "guest authors" who did not analyze the data or write the manuscript, and sometimes were not involved in the trial at all.

And from the accompanying editorial:

"It is difficult to believe that full-time faculty members can generate outside income greater than their salaries without shortchanging their institutions and their students."


References

  1. Bodenheimer T. Uneasy Alliance -- Clinical Investigators and the Pharmaceutical Industry. New England Journal of Medicine May 18, 2000; volume 342, number 20, pages 1539- 1544.

  2. Angell M. Is Academic Medicine for Sale? New England Journal of Medicine May 18, 2000; volume 342, number 20, pages 1516-1518.



ISSN # 1052-4207

Copyright 2000 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.


Back to the AIDS Treatment News June 2, 2000 contents page.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
 
See Also
More News and Info on Clinical Trials

Tools
 

Advertisement